Dantrolene: An Exon Skipping Enhancing Drug

Drs. Carrie Miceli and Stan Nelson at UCLA are developing an FDA approved drug that could boost the effectiveness of exon skipping drugs that are being developed and tested for Duchenne muscular dystrophy.

Drs. Miceli and Nelson in collaboration with Dr. Melissa Spencer, have tested dantrolene in combination with morpholinos in the mdx mouse, the mouse model for Duchenne.  The  increase in effectiveness is significant given the difficulty and high price of producing morpholinos.  Any reduction in the amount of morpholinos that need to be administered will greatly benefit the Duchenne patients and community.

Read more:  https://medicalxpress.com/news/2012-12-scientists-drug-duchenne-muscular-dystrophy.html

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.